title: Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
abstract: OBJECTIVE
  Gc protein-derived macrophage-activating factor (GcMAF) has various functions as an immune modulator, such as macrophage activation, anti-angiogenic activity and anti-tumor activity. Clinical trials of second-generation GcMAF demonstrated remarkable clinical effects in several types of cancers. Thus, GcMAF-based immunotherapy has a wide application for use in the treatment of many diseases via macrophage activation that can be used as a supportive therapy. Multiple sclerosis (MS) is considered to be an autoimmune disorder that affects the myelinated axons in the central nervous system (CNS). This study was undertaken to examine the effects of second-generation GcMAF in a patient with MS.
  
  
  RESULTS
  This case study demonstrated that treatments of GcMAF in a patient with MS have potent therapeutic actions with early beneficial responses, especially improvement of motor dysfunction.
  
  
  CONCLUSIONS
  GcMAF shows therapeutic potency in the treatment of MS.
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Kobe Saisei Mirai Clinic, Kobe, Japan Inui Immunotherapy Clinic, Osaka, Japan contact@saisei-mirai.or.jp.
authors.forename: Toshio
authors.initials: T
authors.lastname: Inui
authors.affiliation: Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
authors.forename: Goro
authors.initials: G
authors.lastname: Katsuura
authors.affiliation: Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kubo
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kuchiike
authors.affiliation: Inui Immunotherapy Clinic, Osaka, Japan.
authors.forename: Leslye
authors.initials: L
authors.lastname: Chenery
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Uto
authors.affiliation: Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan.
authors.forename: Takahito
authors.initials: T
authors.lastname: Nishikata
authors.affiliation: Inui Immunotherapy Clinic, Osaka, Japan contact@saisei-mirai.or.jp.
authors.forename: Martin
authors.initials: M
authors.lastname: Mette
mesh_terms: D000368:Aged; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy; D008124:Locomotion / Q000187:drug effects; D016215:Macrophage-Activating Factors / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D012074:Remission Induction; D016896:Treatment Outcome; D014809:Vitamin D-Binding Protein / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007155:Immunologic Factors; D016215:Macrophage-Activating Factors; D014809:Vitamin D-Binding Protein; C101908:vitamin D-binding protein-macrophage activating factor
keywords: GcMAF; Immunotherapy; colostrum MAF; macrophage activating factor (MAF); motor dysfunction; multiple sclerosis